Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GlaxoSmithKline to increase its ownership in Theravance
GSK will acquire, 10,000,000 shares of Theravance common stock at a price of $21.2887 per share, for a total investment of $212,887,000.
-
Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV
SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir compared to raltegravir over 48 weeks in treatment of HIV patients.
-
GSK and Theravance announce completion of the Relovair™* registrational programme and topline results from Relovair™ vs. Advair® phase III studies in COPD
GSK & THNX announced study results for Relovair in patients with COPD evaluating the efficacy compared to placebo in treatment of asthma
-
GSK confirms significant investments in UK manufacturing: Ulverston in Cumbria selected as site of new biopharmaceutical factory
GSK today confirmed it will invest over 163m in the UK manufacturing sites to increase production of pharmaceutical products & vaccines
-
GSK announces positive vote from FDA panel for pazopanib in certain advanced soft tissue sarcomas
GSK announced the ODAC voted 11:2 in support a favourable benefit; risk assessment for use of Votrient in patients with soft tissue sarcoma.
-
GlaxoSmithKline provides further update on divestment of non-core over-the-counter (OTC) brands
GSK announced intention to divest Consumer Healthcare OTC products predominantly in the US & EU with aggregate sales of approx 163million.
-
GSK reinforces commitment to youth training with launch of new UK apprenticeship programme
GSK announced launch of a new apprenticeship scheme. The programme will sit alongside GSK's established schemes & is aimed at 16-24yo
-
Regulatory Update: GSK announces submissions for two influenza vaccines
GSK announced today that it has submitted regulatory files for two of its influenza vaccines currently in development.
-
Innovative UK research project to study the value medicines bring to patients in the real world
Unique collaboration to ensure medicines under development meet patient and healthcare system needs.
-
GSK and Daiichi Sankyo vaccines joint venture to become largest vaccines company in Japan
GSK announced that it has signed an agreement with Daiichi Sankyo Co., Ltd. to form JV expected to create #1 vaccines company in Japan.
-
GlaxoSmithKline receives positive opinion in Europe from the CHMP for Nimenrix®
GSK announced that EMA's CHMP is recommending marketing authorisation for Nimenrix for immunisation against meningococcal disease
-
EU and US Regulatory Update – Tykerb/Tyverb® (lapatinib)
GSK announced it has submitted regulatory applications in EU & US related to Tykerb/ Tyverb (lapatinib) to treat metastatic breast cancer.
-
GSK results announcement for Q4 and full year 2011
GSK delivers continued underlying sales growth*, R&D progress and improving financial returns to shareholders
-
GSK joins new global partnership to help defeat ten neglected tropical diseases by 2020
GSK announced it has joined other global pharma companies and organisations in a united effort to defeat neglected tropical diseases.
-
GSK announces changes to the Board
GSK announced at annual GM in 2013,that Sir Crispin Davis, Sir Robert Wilson and Mr Larry Culp will not stand for re-election to the Board.
-
GSK responds to the recent court ruling on the COMPAS study in Mendoza, Argentina
GSK respectfully disagrees with court ruling in favour of ANMAT on fine issued regarding conduct of the COMPAS study in Mendoza, Argentina
-
GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily Relovair™* in COPD and asthma
GSK & THRX announced completion of phase III registration programme for Relovair in patients with COPD and in patients with asthma.
-
GlaxoSmithKline provides update on divestment of non-core over-the-counter (OTC) brands
Agreement reached to divest brands in USA and Canada to Prestige Brands Holdings, Inc. for £426m ($660m).
-
GlaxoSmithKline and Human Genome Sciences initiate phase III trial of belimumab (Benlysta®) administered subcutaneously in subjects with systemic lupus erythematosus
GSK & HGS announced dosing has been initiated in BLISS-SC, a new Phase III study of belimumab administered SC to adults with SLE.
-
GSK extends pneumococcal vaccine agreement with GAVI Alliance
GSK & GAVI to help protect millions more children in the world's poorest countries from pneumococcal disease.